Symbiosis Earns Recognition from EcoVadis for Commitment to Sustainability

 
Symbiosis Pharmaceutical Services, a leading Contract Manufacturing Organisation (CMO) specialising in sterile GMP manufacturing of biopharmaceuticals, has been recognised by EcoVadis, the globally trusted provider of business sustainability ratings.

Symbiosis has been awarded a Committed Badge through the EcoVadis recognition system for its efforts in carbon reduction and alignment with the Science Based Targets initiative (SBTi).

The recognition underscores Symbiosis' commitment to driving sustainability in the pharmaceutical supply chain by implementing environmental, social, and governance (ESG) principles across its operations.

As part of its sustainability action plan, Symbiosis has calculated its carbon footprint and set clear reduction targets.

It is introducing several strategic initiatives to lower its environmental impact including introducing 100% renewable electricity powering operations, heat recovery systems and use of air source heat pumps to support the HVAC system to enhance energy efficiency, and water conservation via recirculation. [AC1] 

These initiatives will save a projected CO₂ reduction of 151.7 tonnes[2] , and will see a 37% reduction in emissions after[AC3]  transitioning to 100% renewable energy in 2025.

“As we continue to expand our world class sterile manufacturing operations, sustainability remains a key consideration at the heart of our growth planning,” said Colin MacKay, CEO at Symbiosis. “This recognition from EcoVadis recognises our practical commitment to environmental responsibility, and Symbiosis is proud to take meaningful steps in support of a more sustainable biopharmaceutical industry.

“With demand for Symbiosis’ automated sterile drug manufacturing capacity increasing, the company remains focused on minimising its environmental impact while delivering high-quality, GMP-compliant solutions to our clients around the world.”

Headquartered in Stirling, UK, and specialising in the sterile manufacture (fill/finish) of pharmaceuticals and biopharmaceuticals for clinical trials and the supply of commercial markets, Symbiosis most recently reported a successful routine FDA inspection of its facilities and quality system.

The company continues its physical and operational expansion with the completion of its new state-of-the-art automated sterile GMP manufacturing facility, close to its existing facilities in Stirling, UK. This will increase the company’s sterile manufacturing capabilities, enabling it to support a growing number of clients globally through the clinical and commercial injectable drug product lifecycle challenges.